Drug maker AstraZeneca is pink-slipping approximately 550 Wilmington, Delaware-based researchers and their support staff in a move to help balance the company's books and save it $1.9 billion per year by 2014.
The company told the linkurl:__Philadelphia Inquirer__;http://www.philly.com/philly/business/86127882.html yesterday (March 3rd) that the layoffs are part of a plan to shutter an entire research group, focused on identifying candidate compounds for psychiatric diseases. The staff in Wilmington will lose their jobs by the end of 2011. The impending cuts likely explain why the pharmaceutical company declined to quantify its new R&D hires when we recently requested it for an upcoming project. In mid-2008, AstraZeneca's Vice President of Continuous Improvement and Business Performance, Karen Gotting-Smith, linkurl:told;http://www.the-scientist.com/2008/9/1/69/1/ __The Scientist__ she hoped her newly created position would help the company streamline its drug development process while increasing quality and lowering costs. "My role now is to work with...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?